New hope for psoriasis: oral drug shows promise in chinese trial

NCT ID NCT06122649

Completed Disease control Sponsor: Amgen Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested the drug apremilast (Otezla) in 203 Chinese adults with moderate to severe plaque psoriasis. Participants took either apremilast or a placebo pill twice daily for 16 weeks. The main goal was to see if more people on apremilast achieved at least a 75% improvement in their psoriasis skin symptoms compared to placebo.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: apremilast (Otezla)
What this could lead to: If successful, this could provide a new oral treatment option for Chinese patients with moderate to severe plaque psoriasis, helping clear skin and reduce itching.
What could go wrong: This is a completed Phase 3 trial, but results may not apply to all populations. Apremilast can cause side effects like nausea, diarrhea, and headache. It controls symptoms but does not cure psoriasis.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

psoriasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PLAQUE PSORIASIS

Contacts and locations

Locations

Changshu No2 Peoples Hospital

Suzhou, Jiangsu, 215006, China
Chengdu Second Peoples Hospital

Chengdu, Sichuan, 610017, China
Dermatology Hospital of Jiangxi Province

Nanchang, Jiangxi, 330000, China
Dermatology Hospital of Southern Medical University

Guangzhou, Guangdong, 510091, China
General Hospital of Ningxia Medical University

Yinchuan, Ningxia, 750003, China
Nanyang First Peoples Hospital

Nanyang, Henan, 473002, China
Peking University First Hospital

Beijing, Beijing Municipality, 100034, China
Peking University Third Hospital

Beijing, Beijing Municipality, 100191, China
Peoples Hospital of Xinjiang Uygur Autonomous Region

Ürümqi, Xinjiang, 830001, China
Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine

Shanghai, Shanghai Municipality, 200025, China
Shandong Provincial Hospital For Skin Diseases,Shandong First Medical University

Jinan, Shandong, 830001, China
Shanghai Skin Disease Hospital

Shanghai, Shanghai Municipality, 200443, China
Sir Run Run Shaw Hospital Affiliated to Zhejiang University School of Medicine

Hangzhou, Zhejiang, 310016, China
The First Affiliated Hospital of Fujian Medical University

Fuzhou, Fujian, 350000, China
The First Bethune Hospital of Jilin University

Changchun, Jilin, 130021, China
The Second Affiliated Hospital of Chongqing Medical University

Chongqing, Sichuan, 400010, China
The Second Hospital of Hebei Medical University

Shijiazhuang, Hebei, 050000, China
The Second Xiangya Hospital of Central South University

Changsha, Hunan, 410011, China
Tianjin Medical University General Hospital

Tianjin, Tianjin Municipality, 300052, China
Wuxi Peoples Hospital

Wuxi, Jiangsu, 241023, China
Yichang Central Peoples Hospital

Yichang, Hubei, 443003, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.